ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1875

Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin

Sangmee Bae1, emmanuelle Faure-Kumar1, Jennifer Wang2, Ani Shahbazian2, linh Truong2, Howard Yang2, Maureen McMahon1, John FitzGerald1 and Christina Charles-Schoeman3, 1University of California Los Angeles, Los Angeles, CA, 2UCLA Medical Center, Los Angeles, CA, 3Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

Meeting: ACR Convergence 2022

Keywords: Cohort Study, COVID-19, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled donor plasma and intravenous immunoglobulin products (IVIG) since May 2020 (C Romero 2021 PMID 33606999). It is not known whether regular administration of IVIG increases circulating anti-SARS-CoV-2 antibodies (COVID ab). The current work evaluates COVID ab titers in patients with idiopathic inflammatory myopathies (IIM) who receive regular treatments with IVIG (IVIG group) compared to a matched control IIM population not receiving IVIG (non-IVIG group).

Methods: Stored plasma samples drawn between March 2021 and February 2022 from a single center longitudinal IIM cohort were analyzed from 25 patients receiving regular IVIG treatment and 20 patients not receiving IVIG with a similar age, sex, and ethnicity distribution. All patients selected had at least 1 COVID mRNA vaccine prior to the blood draw. Pre-vaccination stored samples were also analyzed for 20 and 10 patients in the IVIG and non-IVIG groups respectively (23/30 samples collected pre-pandemic). Antibody testing was performed using a chemiluminescent microparticle immunoassay (AN Gray et al. 2021. PMID 34748607). Univariate and multivariate linear regression analyses were used to evaluate predictors of COVID ab titers. COVID ab titers were log transformed in linear models.

Results: Patients in the IVIG and non-IVIG groups were overall similar in clinical characteristics with the exception of more patients in the IVIG group receiving mycophenolate and less receiving hydroxychloroquine. No significant differences in COVID ab levels were noted between IVIG and non-IVIG groups with a trend for lower COVID ab levels in the IVIG group (Figure 1). In univariate regression analysis of all post vaccination patient samples (IVIG and non-IVIG groups) higher number of vaccine doses was significantly associated with higher COVID ab levels (regression coefficient [95% CI], 2.84[1.10-4.57] log AU/mL, p=0.002). Time duration between last vaccine to specimen collection was not associated with COVID ab levels (regression coefficient [95% CI], 0.003 [-0.01-0.01] log AU/mL, p=0.63). In a multivariate linear regression model evaluating predictors of COVID ab levels, use of IVIG was not a predictor of COVID ab titer after adjusting for other medication differences in bivariate analysis including mycophenolate and hydroxychloroquine.

Antibody levels were negative in all pre-vaccination samples including the 7 samples collected after the pandemic onset (March 2020) which included 4 patients receiving IVIG. In multivariate analysis evaluating predictors of COVID ab levels in only IVIG group, COVID ab levels were not associated with time duration between last IVIG and specimen collection, dose of IVIG at last infusion, total monthly dose of IVIG, or schedule of IVIG treatments (weekly or bi-weekly vs monthly) (Table 2).

Conclusion: No significant differences in COVID ab titers were observed between IIM patients receiving regular treatments with IVIG compared to a matched IIM cohort not receiving IVIG.

Supporting image 1

Values are reported as mean SD or n(%) or median (IQR).
*p<0.05 by student’s t-test for normally distributed data (values reported as mean SD), Wilcoxon test for skewed data (values reported as median(IQR)) or chi-square test for count data.
Antibody testing was performed using a chemiluminescent microparticle immunoassay to detect IgG antibodies against the RBD domain of the Spike protein per the manufacturer’s instructions and previously published protocols (AN Gray et al. 2021. PMID 34748607). Positive anti-Spike IgG titers were defined as equal to or more than 50 arbitrary units per milliliter (AU/mL). Negative titers were <50 AU/mL.

Supporting image 2

Supporting image 3


Disclosures: S. Bae, None; e. Faure-Kumar, None; J. Wang, None; A. Shahbazian, None; l. Truong, None; H. Yang, None; M. McMahon, None; J. FitzGerald, None; C. Charles-Schoeman, AbbVie, Bristol Myers Squibb (BMS), Pfizer, Regeneron-Sanofi, Gilead.

To cite this abstract in AMA style:

Bae S, Faure-Kumar e, Wang J, Shahbazian A, Truong l, Yang H, McMahon M, FitzGerald J, Charles-Schoeman C. Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/assessment-of-antibody-levels-to-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-in-patients-with-idiopathic-inflammatory-myopathies-receiving-treatment-with-intravenous-immunoglobulin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-antibody-levels-to-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-in-patients-with-idiopathic-inflammatory-myopathies-receiving-treatment-with-intravenous-immunoglobulin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology